|
Jul 29
|
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
|
|
Jul 29
|
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
|
|
Jul 29
|
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
|
|
Jul 29
|
Eisai Shares Sink on Surprise EU Rejection of Alzheimer’s Drug
|
|
Jul 27
|
This Biogen Insider Increased Their Holding In The Last Year
|
|
Jul 26
|
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
|
|
Jul 26
|
EU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen
|
|
Jul 26
|
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
|
|
Jul 26
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
|
Jul 26
|
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval
|
|
Jul 26
|
Leqembi voted down by European regulators
|
|
Jul 26
|
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
|
|
Jul 25
|
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 25
|
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
|
Jul 24
|
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
|
|
Jul 24
|
Sage Therapeutics Stock Slides as Pipeline Thins
|
|
Jul 24
|
Is Biogen (BIIB) an Underappreciated Stock?
|
|
Jul 24
|
Biogen, Sage tremor drug fails key trial
|
|
Jul 24
|
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|